NASDAQ:ALBO - Albireo Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$32.86 +0.04 (+0.12 %)
(As of 05/20/2018 03:40 PM ET)
Previous Close$32.86
Today's Range$32.32 - $33.34
52-Week Range$15.31 - $39.87
Volume55,790 shs
Average Volume63,798 shs
Market Capitalization$392.41 million
P/E Ratio-10.43
Dividend YieldN/A
Beta1.61

About Albireo (NASDAQ:ALBO)

Albireo logoAlbireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase II clinical trial for treating progressive familial intrahepatic cholestasis and primary biliary cholangitis. The company's clinical-stage product candidates comprise Elobixibat, an orally administered IBAT inhibitor, which is in Phase III clinical trial for the treatment of chronic constipation and other GI diseases; and A3384, a development stage product to treat bile acid malabsorption. It has license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Receive ALBO News and Ratings via Email

Sign-up to receive the latest news and ratings for ALBO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALBO
CUSIPN/A
Phone857-254-5555

Debt

Debt-to-Equity RatioN/A
Current Ratio27.27
Quick Ratio27.27

Price-To-Earnings

Trailing P/E Ratio-10.43
Forward P/E Ratio38.66
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$13.41 per share
Price / Book2.45

Profitability

EPS (Most Recent Fiscal Year)($3.15)
Net Income$-24,410,000.00
Net MarginsN/A
Return on Equity-21.17%
Return on Assets-17.56%

Miscellaneous

Employees22
Outstanding Shares11,940,000

Albireo (NASDAQ:ALBO) Frequently Asked Questions

What is Albireo's stock symbol?

Albireo trades on the NASDAQ under the ticker symbol "ALBO."

How were Albireo's earnings last quarter?

Albireo (NASDAQ:ALBO) posted its quarterly earnings results on Thursday, May, 17th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $3.75 by $3.90. The biopharmaceutical company earned $11.20 million during the quarter, compared to analysts' expectations of $55.33 million. View Albireo's Earnings History.

What price target have analysts set for ALBO?

5 equities research analysts have issued 1 year target prices for Albireo's stock. Their forecasts range from $50.00 to $92.00. On average, they anticipate Albireo's share price to reach $63.75 in the next year. View Analyst Ratings for Albireo.

What are Wall Street analysts saying about Albireo stock?

Here are some recent quotes from research analysts about Albireo stock:
  • 1. According to Zacks Investment Research, "Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States. " (3/30/2018)
  • 2. Needham & Company LLC analysts commented, "Albireo mgmt hosted a 4Q17 conference call today to provide a corporate update. Company remains on track for initiation of Phase 3 testing of IBAT inhibitor A4250 in Progressive Familiar Intrahepatic Cholestasis (PFIC) in the near future. As a reminder, Albireo presented encouraging data from a Phase 2 trial in rare pediatric cholestatic liver diseases, including PFIC, in 2017. Mgmt guided for Phase 3 top-line results by YE19, w/ regulatory submissions shortly thereafter. Albireo also plans to evaluate elobixibat in Non-Alcoholic Steatohepatitis (NASH), although not until early 2019. Evaluation of A4250 in other rare pediatric cholestatic liver diseases and testing of A3384 in Bile Acid Malabsorption is still planned, but deprioritized in order to focus on A4250 in PFIC. We believe stock is undervalued and reiterate BUY." (3/15/2018)
  • 3. Wedbush analysts commented, "Zynerba updated its plans to focus development on rare and near-rare neurological and psychiatric disorders." (1/3/2018)
  • 4. Cowen Inc analysts commented, "Albireo reported 3Q earnings today and provided a brief summary of recent progress." (11/17/2017)

Who are some of Albireo's key competitors?

Who are Albireo's key executives?

Albireo's management team includes the folowing people:
  • Mr. Ronald H. W. Cooper, Chief Exec. Officer, Pres and Director (Age 55)
  • Dr. Jan P. Mattsson Ph.D., Chief Operating Officer (Age 54)
  • Mr. Peter A. Zorn, Chief Corp. Officer, Gen. Counsel & Sec. (Age 48)
  • Dr. Per-Goran Gillberg Ph.D., Co-Founder and VP of Devel.
  • Mr. Thomas A. Shea MBA, Chief Financial Officer and Treasurer (Age 58)

Has Albireo been receiving favorable news coverage?

News articles about ALBO stock have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Albireo earned a media sentiment score of 0.18 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 45.27 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Albireo's major shareholders?

Albireo's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Artal Group S.A. (4.59%), Federated Investors Inc. PA (2.60%), BVF Inc. IL (1.88%), Millennium Management LLC (1.30%), Heartland Advisors Inc. (0.76%) and Chicago Capital LLC (0.76%). Company insiders that own Albireo stock include Life Sciences Maste Perceptive, Phase4 Partners Ltd and Plc Astrazeneca. View Institutional Ownership Trends for Albireo.

Which major investors are buying Albireo stock?

ALBO stock was acquired by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Artal Group S.A., BVF Inc. IL, Millennium Management LLC, Heartland Advisors Inc., Chicago Capital LLC, BlackRock Inc. and Victory Capital Management Inc.. View Insider Buying and Selling for Albireo.

How do I buy shares of Albireo?

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Albireo's stock price today?

One share of ALBO stock can currently be purchased for approximately $32.86.

How big of a company is Albireo?

Albireo has a market capitalization of $392.41 million. The biopharmaceutical company earns $-24,410,000.00 in net income (profit) each year or ($3.15) on an earnings per share basis. Albireo employs 22 workers across the globe.

How can I contact Albireo?

Albireo's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at 857-254-5555 or via email at [email protected]


MarketBeat Community Rating for Albireo (ALBO)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  140 (Vote Underperform)
Total Votes:  264
MarketBeat's community ratings are surveys of what our community members think about Albireo and other stocks. Vote "Outperform" if you believe ALBO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALBO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Albireo (NASDAQ:ALBO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Albireo in the last 12 months. Their average twelve-month price target is $63.75, suggesting that the stock has a possible upside of 94.00%. The high price target for ALBO is $92.00 and the low price target for ALBO is $50.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $63.75$63.75$66.6667$61.6667
Price Target Upside: 94.00% upside88.83% upside94.36% upside137.27% upside

Albireo (NASDAQ:ALBO) Consensus Price Target History

Price Target History for Albireo (NASDAQ:ALBO)

Albireo (NASDAQ:ALBO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/20/2018WedbushReiterated RatingOutperform$63.00LowView Rating Details
4/20/2018Jefferies GroupInitiated CoverageBuy$50.00HighView Rating Details
3/15/2018Needham & Company LLCInitiated CoverageBuy$50.00HighView Rating Details
11/17/2017CowenReiterated RatingBuyN/AView Rating Details
11/15/2017Roth CapitalInitiated CoverageBuy ➝ Buy$92.00N/AView Rating Details
2/16/2017Ladenburg ThalmannInitiated CoverageBuyN/AView Rating Details
1/25/2017William BlairInitiated CoverageOutperformN/AView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Albireo (NASDAQ:ALBO) Earnings History and Estimates Chart

Earnings by Quarter for Albireo (NASDAQ:ALBO)

Albireo (NASDAQ:ALBO) Earnings Estimates

2018 EPS Consensus Estimate: $0.94
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$3.57$4.05$3.81
Q2 20182($0.90)($0.86)($0.88)
Q3 20182($0.99)($0.87)($0.93)
Q4 20182($1.07)($1.06)($1.07)

Albireo (NASDAQ ALBO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/17/2018Q1 2018$3.75($0.15)$55.33 million$11.20 millionViewListenView Earnings Details
3/15/2018Q4 2017($0.78)($0.55)ViewListenView Earnings Details
11/14/2017Q3 2017($0.85)($0.73)ViewN/AView Earnings Details
8/21/20176/30/2017($0.84)($0.86)ViewN/AView Earnings Details
5/10/2017Q2 2017($1.1050)($1.06)ViewN/AView Earnings Details
8/11/2016Q216($0.05)ViewN/AView Earnings Details
5/9/2016Q2($0.04)($0.09)ViewN/AView Earnings Details
2/16/2016Q1($0.08)($0.05)ViewN/AView Earnings Details
12/17/2015Q315($0.11)($0.05)ViewListenView Earnings Details
8/13/2015Q3($0.10)($0.12)ViewListenView Earnings Details
5/6/2015Q215($0.23)($0.27)ViewN/AView Earnings Details
2/12/2015Q115($0.18)($0.20)ViewN/AView Earnings Details
12/17/2014Q414($0.27)($0.16)ViewN/AView Earnings Details
8/11/2014Q2 2014($0.26)($0.15)ViewN/AView Earnings Details
5/13/2014Q114($0.26)($0.29)ViewN/AView Earnings Details
2/6/2014Q4($0.19)($0.20)ViewN/AView Earnings Details
12/18/2013Q4($0.30)($0.04)ViewListenView Earnings Details
8/12/2013Q3 2013($0.37)($0.66)ViewN/AView Earnings Details
5/8/2013Q2 2013($0.43)($0.37)ViewN/AView Earnings Details
2/12/2013Q4 2012($12.91)($12.61)ViewN/AView Earnings Details
12/18/2012Q3 2012($13.81)($12.31)ViewN/AView Earnings Details
8/8/2012Q2 2012($16.22)($13.39)ViewN/AView Earnings Details
5/10/2012Q1 2012($18.02)($13.33)ViewN/AView Earnings Details
2/8/2012Q4 2011($16.82)($13.93)ViewN/AView Earnings Details
12/6/2011Q3 2011($20.42)($15.86)ViewN/AView Earnings Details
8/4/2011Q2 2011($25.23)($17.66)ViewN/AView Earnings Details
5/5/2011Q1 2011($31.23)($24.74)ViewN/AView Earnings Details
2/3/2011Q4 2010($33.63)($24.14)ViewN/AView Earnings Details
12/9/2010Q3 2010($44.44)($37.24)ViewN/AView Earnings Details
8/5/2010Q2 2010($48.05)($43.24)ViewN/AView Earnings Details
5/6/2010Q1 2010($50.45)($52.37)ViewN/AView Earnings Details
2/4/2010Q4 2009($51.65)($56.10)ViewN/AView Earnings Details
12/14/2009Q3 2009($60.06)($52.97)ViewN/AView Earnings Details
8/7/2009Q2 2009($61.26)($56.34)ViewN/AView Earnings Details
5/7/2009Q1 2009($50.45)($58.86)ViewN/AView Earnings Details
2/5/2009Q4 2008($50.45)($50.81)ViewN/AView Earnings Details
12/10/2008Q3 2008($54.05)($63.66)ViewN/AView Earnings Details
8/6/2008Q2 2008($54.05)($51.29)ViewN/AView Earnings Details
5/9/2008Q1 2008($56.46)($52.13)ViewN/AView Earnings Details
2/14/2008Q4 2007($54.05)($65.59)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Albireo (NASDAQ:ALBO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Albireo (NASDAQ ALBO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.60%
Institutional Ownership Percentage: 29.35%
Insider Trading History for Albireo (NASDAQ:ALBO)
Institutional Ownership by Quarter for Albireo (NASDAQ:ALBO)

Albireo (NASDAQ ALBO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/30/2018Phase4 Partners LtdMajor ShareholderSell100,000$34.44$3,444,000.00View SEC Filing  
1/25/2018Life Sciences Maste PerceptiveMajor ShareholderBuy275,000$33.00$9,075,000.00View SEC Filing  
12/1/2017Plc AstrazenecaMajor ShareholderSell500,000$21.40$10,700,000.00View SEC Filing  
12/20/2013Brian Jg PereiraDirectorSell4,734$2.26$10,698.84View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Albireo (NASDAQ ALBO) News Headlines

Source:
DateHeadline
Albireo Pharma (ALBO) Reports Q1 Loss of $0.15, Miss on RevenuesAlbireo Pharma (ALBO) Reports Q1 Loss of $0.15, Miss on Revenues
www.streetinsider.com - May 18 at 10:26 AM
Albireo (ALBO) Issues Quarterly  Earnings Results, Beats Expectations By $0.95 EPSAlbireo (ALBO) Issues Quarterly Earnings Results, Beats Expectations By $0.95 EPS
www.americanbankingnews.com - May 18 at 8:15 AM
Albireo (ALBO) Receives Consensus Rating of "Buy" from AnalystsAlbireo (ALBO) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 18 at 3:48 AM
Albireo (ALBO) Lifted to "Hold" at BidaskClubAlbireo (ALBO) Lifted to "Hold" at BidaskClub
www.americanbankingnews.com - May 17 at 4:53 PM
BRIEF-Albireo Qtrly Net Loss Per Share - Basic And Diluted $0.15BRIEF-Albireo Qtrly Net Loss Per Share - Basic And Diluted $0.15
www.reuters.com - May 17 at 9:47 AM
Albireo Provides First Quarter 2018 Business UpdateAlbireo Provides First Quarter 2018 Business Update
finance.yahoo.com - May 17 at 9:47 AM
BRIEF-Albireo Enrolls First Patient In Phase 3 PFIC Trial Of A4250BRIEF-Albireo Enrolls First Patient In Phase 3 PFIC Trial Of A4250
www.reuters.com - May 16 at 9:48 AM
Albireo Pharma (ALBO) Reports First Patient Enrollment in Phase 3 PFIC Trial of A4250Albireo Pharma (ALBO) Reports First Patient Enrollment in Phase 3 PFIC Trial of A4250
www.streetinsider.com - May 16 at 9:48 AM
Albireo Enrolls First Patient in Phase 3 PFIC Trial of A4250Albireo Enrolls First Patient in Phase 3 PFIC Trial of A4250
finance.yahoo.com - May 16 at 9:48 AM
Albireo (ALBO) Upgraded at BidaskClubAlbireo (ALBO) Upgraded at BidaskClub
www.americanbankingnews.com - May 11 at 9:16 PM
Albireo to Host First Quarter 2018 Business Update Conference Call and Webcast on May 17, 2018Albireo to Host First Quarter 2018 Business Update Conference Call and Webcast on May 17, 2018
finance.yahoo.com - May 9 at 9:36 AM
$55.33 Million in Sales Expected for Albireo (ALBO) This Quarter$55.33 Million in Sales Expected for Albireo (ALBO) This Quarter
www.americanbankingnews.com - May 8 at 2:26 AM
 Brokerages Expect Albireo (ALBO) to Post $3.75 Earnings Per Share Brokerages Expect Albireo (ALBO) to Post $3.75 Earnings Per Share
www.americanbankingnews.com - May 6 at 7:33 PM
Jefferies Starts Albireo Pharma (ALBO) at BuyJefferies Starts Albireo Pharma (ALBO) at Buy
www.streetinsider.com - May 5 at 9:52 AM
Albireo (ALBO) Lowered to Strong Sell at BidaskClubAlbireo (ALBO) Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - May 5 at 12:29 AM
Albireo (ALBO) Rating Increased to Strong-Buy at ValuEngineAlbireo (ALBO) Rating Increased to Strong-Buy at ValuEngine
www.americanbankingnews.com - May 4 at 12:54 AM
Albireo to Present at Deutsche Bank 43rd Annual Health Care ConferenceAlbireo to Present at Deutsche Bank 43rd Annual Health Care Conference
finance.yahoo.com - April 30 at 9:44 AM
Energy Management Control Corporation Joins Albireo EnergyEnergy Management Control Corporation Joins Albireo Energy
www.prnewswire.com - April 25 at 4:33 PM
Albireo Pharma, Inc. (ALBO) Given Average Recommendation of "Buy" by BrokeragesAlbireo Pharma, Inc. (ALBO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 23 at 3:34 AM
 Brokerages Expect Albireo Pharma, Inc. (ALBO) Will Post Quarterly Sales of $55.00 Million Brokerages Expect Albireo Pharma, Inc. (ALBO) Will Post Quarterly Sales of $55.00 Million
www.americanbankingnews.com - April 21 at 2:35 AM
Albireo Pharma (ALBO) Earns "Outperform" Rating from WedbushAlbireo Pharma (ALBO) Earns "Outperform" Rating from Wedbush
www.americanbankingnews.com - April 20 at 4:17 PM
Albireo Pharma (ALBO) Receives New Coverage from Analysts at Jefferies GroupAlbireo Pharma (ALBO) Receives New Coverage from Analysts at Jefferies Group
www.americanbankingnews.com - April 20 at 10:25 AM
 Analysts Expect Albireo Pharma, Inc. (ALBO) Will Post Earnings of $3.81 Per Share Analysts Expect Albireo Pharma, Inc. (ALBO) Will Post Earnings of $3.81 Per Share
www.americanbankingnews.com - April 19 at 5:22 PM
BidaskClub Lowers Albireo Pharma (ALBO) to SellBidaskClub Lowers Albireo Pharma (ALBO) to Sell
www.americanbankingnews.com - April 19 at 11:10 AM
Albireo to Present Data from Two Studies on Cholestatic Liver Disease at the 51st ESPGHAN Annual MeetingAlbireo to Present Data from Two Studies on Cholestatic Liver Disease at the 51st ESPGHAN Annual Meeting
finance.yahoo.com - April 19 at 9:33 AM
Albireo Pharma (ALBO) Receives New Coverage from Analysts at Needham & Company LLCAlbireo Pharma (ALBO) Receives New Coverage from Analysts at Needham & Company LLC
www.americanbankingnews.com - April 17 at 6:29 PM
Albireo Pharma (ALBO) Annoucnes Data on Pharmacodynamic Marker for A4250 in Children with Cholestatic Liver ...Albireo Pharma (ALBO) Annoucnes Data on Pharmacodynamic Marker for A4250 in Children with Cholestatic Liver ...
www.streetinsider.com - April 16 at 9:27 AM
Albireo Reports Data on Pharmacodynamic Marker for A4250 in Children with Cholestatic Liver Disease at The ...Albireo Reports Data on Pharmacodynamic Marker for A4250 in Children with Cholestatic Liver Disease at The ...
globenewswire.com - April 16 at 9:27 AM
Albireo Pharma (ALBO) Downgraded by ValuEngine to "Sell"Albireo Pharma (ALBO) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - April 8 at 2:04 PM
Albireo Pharma, Inc. (ALBO) Expected to Announce Quarterly Sales of $55.00 MillionAlbireo Pharma, Inc. (ALBO) Expected to Announce Quarterly Sales of $55.00 Million
www.americanbankingnews.com - April 4 at 2:30 AM
$3.81 Earnings Per Share Expected for Albireo Pharma, Inc. (ALBO) This Quarter$3.81 Earnings Per Share Expected for Albireo Pharma, Inc. (ALBO) This Quarter
www.americanbankingnews.com - April 2 at 5:16 PM
Albireo Pharma (ALBO) Stock Rating Upgraded by Zacks Investment ResearchAlbireo Pharma (ALBO) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 30 at 4:32 PM
Albireo Pharma, Inc. to Post Q1 2018 Earnings of $3.57 Per Share, Wedbush Forecasts (ALBO)Albireo Pharma, Inc. to Post Q1 2018 Earnings of $3.57 Per Share, Wedbush Forecasts (ALBO)
www.americanbankingnews.com - March 30 at 6:50 AM
Albireo Pharma (ALBO) Presents At Needham And Company 17th Annual Healthcare Conference - SlideshowAlbireo Pharma (ALBO) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 4:23 PM
Albireo Pharma, Inc. (ALBO) Receives Consensus Recommendation of "Buy" from AnalystsAlbireo Pharma, Inc. (ALBO) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 29 at 3:24 AM
Albireo Pharma (ALBO) to Present Clinical Data on A4250 at The International Liver CongressAlbireo Pharma (ALBO) to Present Clinical Data on A4250 at The International Liver Congress
www.streetinsider.com - March 28 at 4:21 PM
Albireo Pharma (ALBO) Lowered to Hold at BidaskClubAlbireo Pharma (ALBO) Lowered to Hold at BidaskClub
www.americanbankingnews.com - March 28 at 11:55 AM
Albireo Pharmas (ALBO) "Outperform" Rating Reaffirmed at WedbushAlbireo Pharma's (ALBO) "Outperform" Rating Reaffirmed at Wedbush
www.americanbankingnews.com - March 28 at 11:11 AM
Albireo to Present Clinical Data on A4250 at The International Liver Congress™ 2018Albireo to Present Clinical Data on A4250 at The International Liver Congress™ 2018
finance.yahoo.com - March 28 at 9:48 AM
Albireo Pharma (ALBO) Upgraded to Buy by BidaskClubAlbireo Pharma (ALBO) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - March 26 at 9:57 AM
Albireo Pharma (ALBO) Stock Rating Upgraded by ValuEngineAlbireo Pharma (ALBO) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 25 at 9:16 PM
Albireo Pharma (ALBO) Stock Rating Upgraded by BidaskClubAlbireo Pharma (ALBO) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 24 at 1:54 PM
Albireo to Present at 17th Annual Needham & Company Healthcare ... - GlobeNewswire (press release)Albireo to Present at 17th Annual Needham & Company Healthcare ... - GlobeNewswire (press release)
globenewswire.com - March 21 at 4:20 PM
Albireo to Present at 17th Annual Needham & Company Healthcare Conference - NasdaqAlbireo to Present at 17th Annual Needham & Company Healthcare Conference - Nasdaq
www.nasdaq.com - March 21 at 10:44 AM
Albireo to Present at 17th Annual Needham & Company Healthcare ConferenceAlbireo to Present at 17th Annual Needham & Company Healthcare Conference
finance.yahoo.com - March 21 at 10:44 AM
Albireo Pharma (ALBO) Lifted to "Hold" at Zacks Investment ResearchAlbireo Pharma (ALBO) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 19 at 5:02 PM
Q1 2018 EPS Estimates for Albireo Pharma, Inc. (ALBO) Raised by William BlairQ1 2018 EPS Estimates for Albireo Pharma, Inc. (ALBO) Raised by William Blair
www.americanbankingnews.com - March 19 at 1:56 AM
Albireo Reports Fourth Quarter and Year-End 2017 Financial Results - GlobeNewswire (press release)Albireo Reports Fourth Quarter and Year-End 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 17 at 9:48 AM
BRIEF-Albireo Reports Fourth Quarter And Year-End 2017 Financial ResultsBRIEF-Albireo Reports Fourth Quarter And Year-End 2017 Financial Results
www.reuters.com - March 15 at 4:51 PM
Albireo Pharma (ALBO) Now Covered by Analysts at Needham & Company LLCAlbireo Pharma (ALBO) Now Covered by Analysts at Needham & Company LLC
www.americanbankingnews.com - March 15 at 4:20 PM

SEC Filings

Albireo (NASDAQ:ALBO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Albireo (NASDAQ:ALBO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Albireo (NASDAQ ALBO) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.